Project 2

项目2

• 批准号: 10005204
• 负责人: Ryan Bruce Corcoran
• 金额: $ 39.96万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-30 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005204
• 关键词: Accounting; Collaborations; Communication; Data Analyses; Data Set; Disease; Drug resistance; Ensure; Experimental Designs; Fostering; Funding; Generations; Genomics; Goals; Institutes; Leadership; Learning; Liquid substance; Logistics; Lung; Maintenance; Manuscripts; Mission; Modeling; Organoids; Patient Care; Patients; Preparation; Process; Progress Reports; Records; Research; Research Personnel; Research Project Grants; Resource Allocation; Resource Sharing; Resources; Science; Site; Structure; Time; Tissues; Translational Research; Ursidae Family; data sharing; data sharing networks; liquid biopsy; meetings; melanoma; success; symposium; translational approach

Given the daunting scope of the challenge of drug resistance, a strong team science approach will be needed to bring a full array of translational research approaches to bear in order to deliver transformative breakthroughs that will impact patient care. In addition to managing fiscal and budgetary oversight, we will coordinate a regular process of collaborative meetings, to be coordinated by the PIs and Project Manager to ensure real-time collaborative data sharing and collective input on data interpretation and experimental design. We will establish shared resource “cores” to provide investigators in this DRSC ready access to several key capabilities that will be crucial for the success of our research project portfolio. These shared resources will include (1) Patient-derived Organoid Generation, (2) Liquid Biopsy, (3) Genomics and (4) tissue acquisition, and allocation of resources will be overseen by the PIs and the Project Manager. The Administrative Core will also interface with key components of the collaborative leadership structure of the DRSCincluding: 1.) Project co-Leaders--Dr. Benes (Project 1), Dr. Heist (Project 2), Dr. Hacohen (Project 3) 2.) Disease Center Leadership—Dr. Shaw (lung), Dr. Flaherty (melanoma), Dr. Corcoran (GI) 3.) Shared Resource Core Leadership—Drs. Benes/Yilmaz (Patient-derived models), Drs. Hacohen/Getz (Genomics), Dr. Juric (Tissue acquisition), Liquid Biopsy (Drs. Adalsteinsson, Corcoran) 4.) DRSC Advisory Board—Drs. Haber, Chabner, Ryan, Hahn, Golub A major goal of the Administrative Core will be to foster collaboration within project teams, between project teams, and with other DRSC sites and the NCI.

鉴于耐药性挑战的艰巨范围，需要强有力的团队科学方法 运用一整套转化研究方法来实现变革 将影响患者护理的突破。除了管理财政和预算监督外，我们还将 协调定期的协作会议流程，由 PI 和项目经理协调，以 确保实时协作数据共享以及数据解释和实验设计的集体输入。 我们将建立共享资源“核心”，为 DRSC 中的调查人员提供对几个关键资源的访问权限 对于我们研究项目组合的成功至关重要。这些共享资源将 包括（1）患者来源的类器官生成，（2）液体活检，（3）基因组学和（4）组织采集， 资源分配将由 PI 和项目经理监督。 行政核心还将与协作领导结构的关键组成部分进行交互 DRSC包括： 1.) 项目共同负责人--Dr. Benes（项目 1）、Heist 博士（项目 2）、Hacohen 博士（项目 3） 2.) 疾病中心领导—Dr. Shaw（肺）、Flaherty 博士（黑色素瘤）、Corcoran 博士（胃肠道） 3.) 共享资源核心领导力——博士。 Benes/Yilmaz（患者衍生模型），Drs。哈科恩/盖茨 （基因组学），Juric 博士（组织采集），液体活检（Adalsteinsson 博士，Corcoran） 4.) DRSC 顾问委员会——博士。哈伯、查布纳、瑞安、哈恩、戈卢布 管理核心的一个主要目标是促进项目团队内部、项目​​之间的协作 团队，以及其他 DRSC 站点和 NCI。